<< DATATRAK International signs two new studies with a global research-based biopharmaceutical company | Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression >>

Read in | English | Español | Português

Genvec to use $2.5 million grant from NIAID for the development of novel cell lines

Published on August 25, 2009 at 8:25 AM · No Comments

GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec's vector production technology.

Funds from this grant, valued at approximately $2.5 million over three years, will be used to support the development of novel cell lines capable of producing vaccine vectors based on different human serotype groups and encoding inhibitory antigens.

"This important grant will support work to advance our cell line technology and enhance GenVec's ability to discover and develop new adenovector-based vaccines and therapeutics," said Dr. Doug Brough, GenVec's Executive Director of Vector Sciences.

http://www.genvec.com

9c187fcf-b7f9-4467-910f-c3f5f8d6a05e|0|.0

Posted in: Device / Technology News

Tags: Allergy, Cancer, Cell, Esophageal Cancer, Head and Neck Cancer, Malaria, Pancreatic Cancer, Vaccine, Virus

Related posts

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCLThe U.S. Food and Drug Administration today approved Adcetris to treat Hodgkin lymphoma and a rare l...
Early knowledge of HCC response to TACE determines treatment success: Research articleEarly knowledge of hepatocellular carcinoma response to transcatheter arterial chemoembolization is ...
Study indicates climate change plays a role in malaria transmissionClimate change is one reason malaria is on the rise in some parts of the world, new research finds, ...
Modified blood adult stem-cell transplant regimen reverses sickle cell diseaseA modified blood adult stem-cell transplant regimen has effectively reversed sickle cell disease in ...
H1N1 infected people continue to shed live virus days after the symptomsABC News and other outlets are reporting that two studies released on Tuesday suggest that people in...
CEL-SCI expands work on current H1N1 virus vaccineCEL-SCI Corporation has announced that it is expanding the scope of its work towards creating a nove...
Cetuximab and chemotherapy combination proves safe, effective for head and neck cancer patientsPatients treated for locally advanced head and neck cancer may respond better to treatment with the ...
Improving diagnosis of pancreatic cancerIn the August issue of Molecular & Cellular Proteomics, scientists provide the first large-scale ide...
Thrombospondin (TSP-1) can cause kidney failure when normal blood flow is disruptedScientists led by a University of Cincinnati (UC) kidney expert have found that a naturally occurrin...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.